|
1
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002. View Article : Google Scholar
|
|
2
|
Bamias G, Nyce MR, De La Rue SA and
Cominelli F; American College of Physicians; American Physiological
Society. New concepts in the pathophysiology of inflammatory bowel
disease. Ann Intern Med. 143:895–904. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Targan SR and Karp LC: Defects in mucosal
immunity leading to ulcerative colitis. Immunol Rev. 206:296–305.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grimm MC, Pullman WE, Bennett GM, Sullivan
PJ, Pavli P and Doe WF: Direct evidence of monocyte recruitment to
inflammatory bowel disease mucosa. J Gastroenterol Hepatol.
10:387–395. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rugtveit J, Brandtzaeg P, Halstensen TS,
Fausa O and Scott H: Increased macrophage subset in inflammatory
bowel disease: apparent recruitment from peripheral blood
monocytes. Gut. 35:669–674. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kondoh T, Hidaka Y, Katoh H, Inoue N and
Saito S: Evaluation of a filtration lymphocytapheresis (LCP) device
for use in the treatment of patients with rheumatoid arthritis.
Artif Organs. 15:180–188. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sawada K, Ohnishi K, Fukui S, et al:
Leukocytapheresis therapy, performed with leukocyte removal filter,
for inflammatory bowel disease. J Gastroenterol. 30:322–329. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ortolano GA, Capetandes A and Wenz B: A
review of leukofiltration therapy for decreasing the morbidity
associated with cardiopulmonary bypass and acute inflammatory bowel
disease. Ther Apher. 6:119–129. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sawada K, Muto T, Shimoyama T, et al:
Multicenter randomized controlled trial for the treatment of
ulcerative colitis with a leukocytapheresis column. Curr Pharm Des.
9:307–321. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yajima T, Takaishi H, Kanai T, et al:
Predictive factors of response to leukocytapheresis therapy for
ulcerative colitis. Ther Apher. 2:115–119. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sasaki M, Tsujikawa T, Fujiyama Y and
Bamba T: Leukocytapheresis therapy for severe ulcerative colitis.
Ther Apher. 2:101–104. 1998. View Article : Google Scholar
|
|
12
|
Kosaka T, Sawada K, Ohnishi K, et al:
Effect of leukocytapheresis therapy using a leukocyte removal
filter in Crohn's disease. Intern Med. 38:102–111. 1999. View Article : Google Scholar
|
|
13
|
Hidaka T, Suzuki K, Matsuki Y, et al:
Filtration leukocytapheresis therapy in rheumatoid arthritis: a
randomized, double-blind, placebo-controlled trial. Arthritis
Rheum. 42:431–437. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ueki Y, Yamasaki S, Kanamoto Y, et al:
Evaluation of filtration leucocytapheresis for use in the treatment
of patients with rheumatoid arthritis. Rheumatology. 39:165–171.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Furuta T, Hotta O, Yusa N, Horigome I,
Chiba S and Taguma Y: Lymphocytapheresis to treat rapidly
progressive glomerulonephritis: a randomised comparison with
steroid-pulse treatment. Lancet. 352:203–204. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dieckgraefe BK, Stenson WF, Korzenik JR,
Swanson PE and Harrington CA: Analysis of mucosal gene expression
in inflammatory bowel disease by parallel oligonucleotide arrays.
Physiol Genomics. 4:1–11. 2000.PubMed/NCBI
|
|
17
|
Lawrance IC, Fiocchi C and Chakravarti S:
Ulcerative colitis and Crohn's disease: distinctive gene expression
profiles and novel susceptibility candidate genes. Hum Mol Genet.
10:445–456. 2001.
|
|
18
|
Heller RA, Schena M, Chai A, et al:
Discovery and analysis of inflammatory disease-related genes using
cDNA microarrays. Proc Natl Acad Sci USA. 94:2150–2155. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Truelove SC and Witts LJ: Cortisone in
ulcerative colitis; final report on a therapeutic trial. Br Med J.
2:1041–1048. 1955. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagase K, Sawada K, Ohnishi K, Egashira A,
Ohkusu K and Shimoyama T: Complications of leukocytapheresis. Ther
Apher. 2:120–124. 1998. View Article : Google Scholar
|
|
21
|
Hashimoto S, Suzuki T, Dong HY, Yamazaki N
and Matsushima K: Serial analysis of gene expression in human
monocytes and macrophages. Blood. 94:837–844. 1999.PubMed/NCBI
|
|
22
|
Hashimoto S, Suzuki T, Dong HY, Nagai S,
Yamazaki N and Matsushima K: Serial analysis of gene expression in
human monocyte-derived dendritic cells. Blood. 94:845–852.
1999.PubMed/NCBI
|
|
23
|
Hashimoto SI, Suzuki T, Nagai S, Yamashita
T, Toyoda N and Matsushima K: Identification of genes specifically
expressed in human activated and mature dendritic cells through
serial analysis of gene expression. Blood. 96:2206–2214. 2000.
|
|
24
|
Nagai S, Hashimoto S, Yamashita T, et al:
Comprehensive gene expression profile of human activated T(h)1- and
T(h)2-polarized cells. Int Immunol. 13:367–376. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Khodursky AB, Peter BJ, Cozzarelli NR,
Botstein D, Brown PO and Yanofsky C: DNA microarray analysis of
gene expression in response to physiological and genetic changes
that affect tryptophan metabolism in Escherichia coli. Proc
Natl Acad Sci USA. 97:12170–12175. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang YH, Dudoit S, Luu P, et al:
Normalization for cDNA microarray data: a robust composite method
addressing single and multiple slide systematic variation. Nucleic
Acids Res. 30:e152002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Baechler EC, Batliwalla FM, Karypis G, et
al: Expression levels for many genes in human peripheral blood
cells are highly sensitive to ex vivo incubation. Genes Immun.
5:347–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rauschmayr T, Groves RW and Kupper TS:
Keratinocyte expression of the type 2 interleukin 1 receptor
mediates local and specific inhibition of interleukin 1-mediated
inflammation. Proc Natl Acad Sci USA. 94:5814–5819. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Odink K, Cerletti N, Bruggen J, et al: Two
calcium-binding proteins in infiltrate macrophages of rheumatoid
arthritis. Nature. 330:80–82. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cui XF, Li HH, Goradia TM, et al:
Single-sperm typing: determination of genetic distance between the
G gamma-globin and parathyroid hormone loci by using the polymerase
chain reaction and allele-specific oligomers. Proc Natl Acad Sci
USA. 86:9389–9393. 1989. View Article : Google Scholar
|
|
31
|
Robertson MW, Albrandt K, Keller D and Liu
FT: Human IgE-binding protein: a soluble lectin exhibiting a highly
conserved interspecies sequence and differential recognition of IgE
glycoforms. Biochemistry. 29:8093–8100. 1990. View Article : Google Scholar
|
|
32
|
Takahashi N, Ueda S, Obata M, Nikaido T,
Nakai S and Honjo T: Structure of human immunoglobulin gamma genes:
implications for evolution of a gene family. Cell. 29:671–679.
1982. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mitsuyama K, Suzuki A, Matsumoto S, et al:
Diminished cytokine signalling against bacterial components in
mononuclear leucocytes from ulcerative colitis patients after
leukocytapheresis. Clin Exp Immunol. 141:130–140. 2005. View Article : Google Scholar
|
|
34
|
Andoh A, Ogawa A, Kitamura K, et al:
Suppression of interleukin-1beta- and tumor necrosis
factor-alpha-induced inflammatory responses by leukocytapheresis
therapy in patients with ulcerative colitis. J Gastroenterol.
39:1150–1157. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Noguchi M, Hiwatashi N, Hayakawa T and
Toyota T: Leukocyte removal filter-passed lymphocytes produce large
amounts of interleukin-4 in immunotherapy for inflammatory bowel
disease: role of bystander suppression. Ther Apher. 2:109–114.
1998. View Article : Google Scholar
|
|
36
|
Gray JX, Haino M, Roth MJ, et al: CD97 is
a processed, seven-transmembrane, heterodimeric receptor associated
with inflammation. J Immunol. 157:5438–5447. 1996.PubMed/NCBI
|
|
37
|
Leemans JC, te Velde AA, Florquin S, et
al: The epidermal growth factor-seven transmembrane (EGF-TM7)
receptor CD97 is required for neutrophil migration and host
defense. J Immunol. 172:1125–1131. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Leng L, Metz CN, Fang Y, et al: MIF signal
transduction initiated by binding to CD74. J Exp Med.
197:1467–1476. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ohkawara T, Nishihira J, Takeda H, et al:
Amelioration of dextran sulfate sodium-induced colitis by
anti-macrophage migration inhibitory factor antibody in mice.
Gastroenterology. 123:256–270. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Salomon P, Pizzimenti A, Panja A, Reisman
A and Mayer L: The expression and regulation of class II antigens
in normal and inflammatory bowel disease peripheral blood monocytes
and intestinal epithelium. Autoimmunity. 9:141–149. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kjeldsen L, Johnsen AH, Sengelov H and
Borregaard N: Isolation and primary structure of NGAL, a novel
protein associated with human neutrophil gelatinase. J Biol Chem.
268:10425–10432. 1993.PubMed/NCBI
|
|
42
|
Nielsen BS, Borregaard N, Bundgaard JR,
Timshel S, Sehested M and Kjeldsen L: Induction of NGAL synthesis
in epithelial cells of human colorectal neoplasia and inflammatory
bowel diseases. Gut. 38:414–420. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Cid MC, Grant DS, Hoffman GS, Auerbach R,
Fauci AS and Kleinman HK: Identification of haptoglobin as an
angiogenic factor in sera from patients with systemic vasculitis. J
Clin Invest. 91:977–985. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Laine E, Couderc R, Roch-Arveiller M,
Vasson MP, Giroud JP and Raichvarg D: Modulation of human
polymorphonuclear neutrophil functions by alpha 1-acid
glycoprotein. Inflammation. 14:1–9. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wispe JR, Clark JC, Burhans MS, Kropp KE,
Korfhagen TR and Whitsett JA: Synthesis and processing of the
precursor for human mangano-superoxide dismutase. Biochim Biophys
Acta. 994:30–36. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Russell L and Forsdyke DR: A human
putative lymphocyte G0/G1 switch gene containing a CpG-rich island
encodes a small basic protein with the potential to be
phosphorylated. DNA Cell Biol. 10:581–591. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Warburton G, Nares S, Angelov N, Brahim
JS, Dionne RA and Wahl SM: Transcriptional events in a clinical
model of oral mucosal tissue injury and repair. Wound Repair Regen.
13:19–26. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Pirila E, Ramamurthy NS, Sorsa T, Salo T,
Hietanen J and Maisi P: Gelatinase A (MMP-2), collagenase-2
(MMP-8), and laminin-5 gamma2-chain expression in murine
inflammatory bowel disease (ulcerative colitis). Dig Dis Sci.
48:93–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Yamaji K, Yang K, Tsuda H and Hashimoto H:
Fluctuations in the peripheral blood leukocyte and platelet counts
in leukocytapheresis in healthy volunteers. Ther Apher. 6:402–412.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Sawada K, Ohnishi K, Kosaka T, et al:
Leukocytapheresis with leukocyte removal filter as new therapy for
ulcerative colitis. Ther Apher. 1:207–211. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Danese S: New therapies for inflammatory
bowel disease: from the bench to the bedside. Gut. 61:918–932.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rutgeerts P, Vermeire S and Van Assche G:
Biological therapies for inflammatory bowel diseases.
Gastroenterology. 136:1182–1197. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Mitsuyama K and Sata M: Gut microflora: a
new target for therapeutic approaches in inflammatory bowel
disease. Expert Opin Ther Targets. 12:301–312. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Duijvestein M, van den Brink GR and Hommes
DW: Stem cells as potential novel therapeutic strategy for
inflammatory bowel disease. J Crohns Colitis. 2:99–106. 2008.
View Article : Google Scholar : PubMed/NCBI
|
